Compare Crowdstrike Holdings Inc (CRWD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs BIO-TECHNE Corp — how do they compare? Crowdstrike Holdings Inc trades at $221.88 (market cap $229.27B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Crowdstrike Holdings Inc is far larger — about 20.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| CRWD | TECH | |
|---|---|---|
Market Cap | $229.27B | $11.24B |
Sector | Technology | Health |
52-Week High | $225.16 | $72.29 |
52-Week Low | $87.56 | $43.31 |
Enterprise Value | $225.54B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $214.42, up 3.39% recently, with a bullish technical signal and strong revenue growth, though valuation multiples are high. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights cybersecurity sector strength and AI-driven demand, supported by sold-out events and industry conferences.
Outlook is positive due to robust revenue expansion and platform adoption, but risks include premium valuations and net income volatility. Analyst consensus is strongly bullish with a $191.74 price target, though current price exceeds this, indicating cautious optimism amid growth prospects.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
